Item 7.01Regulation FD Disclosure.

On December 9, 2019, bluebird bio, Inc. ("bluebird") conducted an investor webcast presenting updated clinical data for the LentiGlobin product candidate in the treatment of patients with transfusion-dependent ?-thalassemia (HGB-204, HGB-207, and HGB-212), for the LentiGlobin product candidate in the treatment of patients with sickle cell disease (HGB-206), and for the bb21217 product candidate in the treatment of patients with relapsed-refractory multiple myeloma (CRB-402), as presented at the 61st Annual Meeting of the American Society of Hematology ("ASH") in Orlando, Florida, as well as clinical data from KarMMa, a pivotal phase 2 study of idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma. A copy of the presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.




Item 8.01Other Events.

On December 9, 2019, bluebird issued a press release announcing data presented at ASH of new data from ongoing studies of LentiGlobin gene therapy for ?-thalassemia (betibeglogene autotemcel) in pediatric, adolescent and adult patients who have transfusion-dependent ?-thalassemia (TDT),

Also on December 9, 2019, bluebird issued a press release announcing data presented at ASH from the ongoing Phase 1 clinical study of bb21217 (CRB-402) of its investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed-refractory multiple myeloma.

The full text of bluebird's press releases regarding these announcements are filed as Exhibits 99.2 and 99.3 to this Current Report on Form 8-K and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits




Exhibit
  No.                                    Description
99.1          Investor presentation provided by bluebird bio, Inc. on December 9,
            2019  .
99.2          Press release issued by bluebird bio, Inc. on December 9, 2019
            regarding data from HGB-204, HGB-207 and HGB-212 studies  .
99.3          Press release issued by bluebird bio, Inc. on December 9, 2019
            regarding data from CRB-402 clinical study  .
104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)




                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses